More than half of people who received a pair of broadly neutralising antibodies (bnAbs) plus the immune-modulating drug N-803 (Anktiva) had delayed viral rebound or maintained a low or suppressed viral load during antiretroviral treatment interruption, according to study results presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025).
Sharps safety in health care goes far beyond personal protective equipment. Amanda Heitman outlines a layered strategy of training, communication, and device innovation aimed at…
Garnering a standing ovation at IAS 2025, Sameer Sah, from Medical Aid for Palestinians, provided a devastating first-hand account of what’s been happening for nearly…
Public Law 119-21 as enacted on July 4, 2025
IAS 2025 delivers a clear message: communities are the frontline, not the afterthought.
Scientific Reports – Identification of low-molecular compounds that inhibit envelope formation of hepatitis B virus
Half of the survivors had multisystem symptoms that resulted in an inability to perform basic activities of living.
The outbreak strains have been linked to multiple suppliers, including one common to both outbreak strains.
Colistin is one of the few remaining options for treating multidrug-resistant Klebsiella pneumoniae.
Medical progress depends on independent journals to advance science without political interference.
No deaths have been recorded in Mississippi this year, but 10 patients have been hospitalized.
